# Effect of Anti-interleukin 5 (IL5) Therapy on Sputum Cells and Cytokines

> **NCT04412044** · PHASE4 · COMPLETED · sponsor: **KU Leuven** · enrollment: 22 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Mepolizumab Injection [Nucala]

## Key facts

- **NCT ID:** NCT04412044
- **Lead sponsor:** KU Leuven
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-01
- **Primary completion:** 2018-05-01
- **Final completion:** 2019-03-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2020-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04412044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04412044, "Effect of Anti-interleukin 5 (IL5) Therapy on Sputum Cells and Cytokines". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04412044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*